102 related articles for article (PubMed ID: 24759674)
1. Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant.
Aubert O; Suberbielle C; Gauthe R; Francois H; Obada EN; Durrbach A
Transplantation; 2014 May; 97(9):946-52. PubMed ID: 24759674
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
4. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
5. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
7. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
Cicora F; Paz M; Mos F; Roberti J
Transpl Immunol; 2013 Dec; 29(1-4):7-10. PubMed ID: 23994721
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
10. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
11. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.
Worthington JE; Martin S; Al-Husseini DM; Dyer PA; Johnson RW
Transplantation; 2003 Apr; 75(7):1034-40. PubMed ID: 12698094
[TBL] [Abstract][Full Text] [Related]
12. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of bortezomib on HLA class I and class II antibody.
Philogene MC; Sikorski P; Montgomery RA; Leffell MS; Zachary AA
Transplantation; 2014 Sep; 98(6):660-5. PubMed ID: 24798311
[TBL] [Abstract][Full Text] [Related]
14. Anti-human leukocyte antigen immunization after early allograft nephrectomy.
Del Bello A; Congy N; Sallusto F; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Cointault O; Lavayssière L; Nogier MB; Game X; Blancher A; Rostaing L; Kamar N
Transplantation; 2012 May; 93(9):936-41. PubMed ID: 22361471
[TBL] [Abstract][Full Text] [Related]
15. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
Süsal C; Opelz G
Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against MICA antigens and kidney-transplant rejection.
Zou Y; Stastny P; Süsal C; Döhler B; Opelz G
N Engl J Med; 2007 Sep; 357(13):1293-300. PubMed ID: 17898098
[TBL] [Abstract][Full Text] [Related]
17. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
[TBL] [Abstract][Full Text] [Related]
18. Prospective iterative trial of proteasome inhibitor-based desensitization.
Woodle ES; Shields AR; Ejaz NS; Sadaka B; Girnita A; Walsh RC; Alloway RR; Brailey P; Cardi MA; Abu Jawdeh BG; Roy-Chaudhury P; Govil A; Mogilishetty G
Am J Transplant; 2015 Jan; 15(1):101-18. PubMed ID: 25534446
[TBL] [Abstract][Full Text] [Related]
19. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
[TBL] [Abstract][Full Text] [Related]
20. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period.
Sánchez-Zapardiel E; Castro-Panete MJ; Castillo-Rama M; Morales P; Lora-Pablos D; Valero-Hervás D; Ruiz-García R; Apaza J; Talayero P; Andrés A; Morales JM; Paz-Artal E
Transplantation; 2013 Jul; 96(1):70-8. PubMed ID: 23624543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]